Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Shares of Bellerophon Therapeutics Inc. (BLPH) plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 "Rebuild" study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated "minimal difference" between studied groups, with none approaching statistical significance. The company said it does not see a path forward for continuing the Rebuild trial. The stock has still rallied 33% year to date, while the iShares Biotechnology exchange-traded fund (IBB) has slipped 1.8% and the S&P 500 has advanced 11.7%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 05, 2023 09:40 ET (13:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
, 
, 
Copyright ©2023. All rights reserved.